Amedisys Inc (NASDAQ:AMED) Director Bruce D. Perkins bought 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was purchased at an average cost of $46.60 per share, with a total value of $93,200.00. Following the completion of the transaction, the director now directly owns 15,825 shares in the company, valued at $737,445. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Amedisys Inc (NASDAQ AMED) traded up 3.21% during mid-day trading on Friday, reaching $48.56. The company’s stock had a trading volume of 440,765 shares. The company has a 50-day moving average of $59.50 and a 200-day moving average of $54.23. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The company has a market cap of $1.64 billion, a P/E ratio of 41.50 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.42 earnings per share. Equities research analysts forecast that Amedisys Inc will post $2.21 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/04/amedisys-inc-amed-director-bruce-d-perkins-buys-2000-shares-of-stock.html.

A number of brokerages recently commented on AMED. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Wednesday, July 26th. Stephens boosted their price objective on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a report on Thursday, May 4th. Zacks Investment Research lowered Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, Royal Bank Of Canada reissued a “hold” rating and set a $56.00 price objective on shares of Amedisys in a report on Monday, June 5th. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company. Amedisys currently has a consensus rating of “Buy” and a consensus target price of $56.50.

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Amedisys by 2,877.7% in the first quarter. BlackRock Inc. now owns 5,676,870 shares of the health services provider’s stock valued at $290,032,000 after buying an additional 5,486,225 shares during the period. Vanguard Group Inc. increased its stake in shares of Amedisys by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock valued at $121,067,000 after buying an additional 63,238 shares during the period. FMR LLC increased its stake in shares of Amedisys by 6.9% in the first quarter. FMR LLC now owns 2,352,632 shares of the health services provider’s stock valued at $120,196,000 after buying an additional 152,632 shares during the period. William Blair Investment Management LLC increased its stake in shares of Amedisys by 8.1% in the first quarter. William Blair Investment Management LLC now owns 1,632,242 shares of the health services provider’s stock valued at $83,391,000 after buying an additional 122,305 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Amedisys by 148.7% in the first quarter. American Century Companies Inc. now owns 1,200,754 shares of the health services provider’s stock valued at $61,347,000 after buying an additional 717,939 shares during the period. 97.81% of the stock is owned by institutional investors.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.